AssayIndex
Growth-hormone axis peptides

Sermorelin

GRF (1-29) · GHRH (1-29) amide · Geref · C149H246N44O42 · monoisotopic 3355.7245 Da. The index holds 96 assay reports on this compound across 14 batches from 10 suppliers.

96 reports14 batchesmedian 98.94 %index spec 98.0 %
Section 1

Analytical fingerprint

Hand-authored chemistry. These properties describe the substance and do not change when a record is added.

Sermorelin's Asn8 deamidation is fast enough to be a real analytical hazard: a vial reconstituted and left at room temperature for a week will show a materially larger +1 Da peak than the same lot assayed dry. The index requires the reconstitution-to-injection interval on all sermorelin submissions and reports the deamidated fraction separately. Where two labs report the same lot with a >0.8 pp purity difference and the lower one has the longer hold time, the index attributes the difference to handling and says so on the batch page.

Molecular formula
C149H246N44O42
Monoisotopic mass
3355.7245Da
Average mass
3357.90Da
Residues
29
Nominal retention (RG-2, 30 min)
12.42min
Retention window
0.30min
Counter-ion as usually shipped
acetate
Typical label claims
2 mg · 5 mg · 10 mg · 15 mg
Analytical difficulty (index scale)
1.10 — straightforward
Purity is a defined quantity
YES
Section 2

Representative chromatogram

Drawn from this page's own medians. Not a scan, not an illustration, and not any single report.

02151430264548605 Sermorelin12.42 min · 98.94 % 12.12 same trace · ×100 vertical expansion, baseline-corrected · main peak off-scale reporting threshold 0.05 % area 05101520253035 Retention time (min) Response (mAU)
Figure 1. A representative Sermorelin trace on the index reference method RG-2, constructed from this page's own numbers: the main peak carries the index median purity of 98.94 % area at the nominal retention time of 12.42 min, and each impurity peak carries the median area the index has observed for that named species at its characteristic retention offset. It is not a scan of any single report — every individual record's own chromatogram is on its own page. The lower panel is the same trace at a stated vertical expansion, baseline-corrected, so the impurities are visible; the main peak runs off-scale there by design. Baseline noise is seeded from the compound slug.
Section 3

What the index has observed

Arithmetic over the 96 records the index holds. Aggregates on this page are computed over the records the index holds, which are not a random sample of the material on the market. Lots that get tested are lots someone chose to test. Read every figure here as a description of this dataset rather than as an estimate of a population.

Median purity 98.94% n=96
Interquartile range 0.83pp n=96
Minimum 97.58% n=96
Maximum 99.83% n=96
Pass rate vs spec 96.9% n=96
Median recovery vs claim 97.6% n=54
Median water 5.19% n=96
Median |mass error| 2.7ppm n=83
07142192.093.094.095.096.097.098.099.0100.092.00–92.25 %: n=092.25–92.50 %: n=092.50–92.75 %: n=092.75–93.00 %: n=093.00–93.25 %: n=093.25–93.50 %: n=093.50–93.75 %: n=093.75–94.00 %: n=094.00–94.25 %: n=094.25–94.50 %: n=094.50–94.75 %: n=094.75–95.00 %: n=095.00–95.25 %: n=095.25–95.50 %: n=095.50–95.75 %: n=095.75–96.00 %: n=096.00–96.25 %: n=096.25–96.50 %: n=096.50–96.75 %: n=096.75–97.00 %: n=097.00–97.25 %: n=097.25–97.50 %: n=097.50–97.75 %: n=297.75–98.00 %: n=198.00–98.25 %: n=1198.25–98.50 %: n=1698.50–98.75 %: n=598.75–99.00 %: n=1799.00–99.25 %: n=2299.25–99.50 %: n=1099.50–99.75 %: n=999.75–100.00 %: n=3median 98.94 Purity (% area) Reports
Figure 2. Purity distribution across all 96 Sermorelin records. Dashed line is this compound's median (98.94 %); the solid vertical is the index acceptance specification for the growth-hormone axis peptides class (98.0 %). Domain is fixed at 92–100 % on every purity histogram on this site so that compounds can be compared by eye — a wide distribution here is a hard compound, a narrow one is an easy one, and neither is a statement about the suppliers.
Section 4

By supplier

Suppliers with fewer than two purity records on this compound are omitted from the figure rather than drawn as a line. The full table, including the thin cells, is on the by-supplier page.

97.497.898.398.799.199.6100.0KPKP: Q1 98.67, median 98.91, Q3 99.20, n=22n=22GGPepsGGPeps: Q1 98.23, median 98.83, Q3 99.14, n=15n=15WXTWXT: Q1 98.03, median 98.28, Q3 98.39, n=14outlier 98.94n=14QYBQYB: Q1 99.17, median 99.35, Q3 99.53, n=12n=12FGPFGP: Q1 99.12, median 99.33, Q3 99.61, n=10n=10HJHJ: Q1 98.93, median 99.08, Q3 99.21, n=9outlier 98.37n=9TFCTFC: Q1 98.50, median 98.71, Q3 99.00, n=7n=7SGNSGN: Q1 98.37, median 98.75, Q3 99.05, n=5n=5 Purity (% area)
Figure 3. Sermorelin purity by supplier, ordered by coverage. The vertical line is the index acceptance specification. Boxes that overlap are suppliers this dataset cannot separate, and most of them overlap.

Full per-supplier table with n= caveats →

Section 5

Characteristic impurities and degradants

The left three columns are authored chemistry — what this molecule characteristically carries and where it elutes. The right three are what the index has actually reported.

Named speciesΔRT (min, RG-2)Δ mass (Da)Seen inMedian % areaMax % area
des-Tyr1 (−163 Da)-0.52-163.063100%0.170.88
deamidated Asn8 (+1 Da)-0.30+0.98499%0.371.59
aspartimide (−18 Da)+0.36-18.01199%0.171.01
truncated (1-25)-1.04-455.24899%0.151.08

Degradation pathways

  • Asn8 deamidation — half-life of days in neutral aqueous solution at room temperature
  • Asp3 aspartimide

Full impurity profile, with what each named species implies about the synthesis →

Section 6

Clinical context

Included because it is routinely misapplied. Trial data describes a licensed medicinal product manufactured under a marketing authorisation, and it does not transfer to research-grade material of unknown provenance.

Sermorelin was approved in the United States for paediatric growth-hormone deficiency diagnosis and withdrawn commercially in 2008.

Section 7

Quarterly coverage

QuarterReportsMedian purityRange
2024-Q10n<3—
2024-Q22299.2798.28–99.80
2024-Q31099.3398.94–99.83
2024-Q41198.4398.01–99.22
2025-Q11798.6297.58–99.09
2025-Q20n<3—
2025-Q3798.7598.01–99.25
2025-Q4499.1698.99–99.22
2026-Q10n<3—
2026-Q21099.0098.37–99.56
2026-Q31598.4098.11–99.57

Quarter-by-quarter detail →

Section 8

Most recent records

The 25 most recent Sermorelin records of 96.
ReportSupplierLotLabQuarterPurity %Water %Recovery %ProvenanceFlagsResult
AX-2026-042057TFCTFC-2605-Y6440Janoshik2026-Q398.683.9498.3Supplier-supplied0PASS
AX-2026-043421WXTWXT-2608-P4867Janoshik2026-Q398.153.09—Supplier-supplied0PASS
AX-2026-043420WXTWXT-2608-P4867Medutest2026-Q398.623.0796.4Supplier-supplied0PASS
AX-2026-043423WXTWXT-2608-P4867Janoshik2026-Q398.283.8698.5Buyer-sourced0PASS
AX-2026-042058TFCTFC-2605-Y6440Nordanalyt2026-Q398.713.69107.1Supplier-supplied0PASS
AX-2026-043422WXTWXT-2608-P4867Medutest2026-Q398.353.59—Supplier-supplied1MARGINAL
AX-2026-043418WXTWXT-2608-P4867Janoshik2026-Q398.472.8889.7Supplier-supplied1MARGINAL
AX-2026-042060TFCTFC-2605-Y6440Nordanalyt2026-Q398.313.3092.4Supplier-supplied0PASS
AX-2026-043419WXTWXT-2608-P4867Janoshik2026-Q398.403.38106.3Supplier-supplied0PASS
AX-2026-042059TFCTFC-2605-Y6440PeptideMeter2026-Q398.993.40104.7Supplier-supplied0PASS
AX-2026-042056TFCTFC-2605-Y6440Janoshik2026-Q399.002.93—Supplier-supplied0PASS
AX-2026-042062TFCTFC-2605-Y6440PeptideMeter2026-Q398.203.83—Supplier-supplied0PASS
AX-2026-042061TFCTFC-2605-Y6440Medutest2026-Q399.574.06—Supplier-supplied0PASS
AX-2026-043424WXTWXT-2608-P4867PeptideMeter2026-Q398.113.56—Laboratory-retained0PASS
AX-2026-043417WXTWXT-2608-P4867Janoshik2026-Q398.313.8891.1Supplier-supplied0PASS
AX-2026-042361HJHJ-2605-A4196Medutest2026-Q298.935.4389.8Supplier-supplied1MARGINAL
AX-2026-042359HJHJ-2605-A4196Kestrel2026-Q299.375.63—Supplier-supplied1MARGINAL
AX-2026-042362HJHJ-2605-A4196PeptideMeter2026-Q298.935.80—Supplier-supplied0PASS
AX-2026-043384CPCCPC-2605-N3532VendorInvestigate2026-Q298.474.7395.5Buyer-sourced1MARGINAL
AX-2026-042360HJHJ-2605-A4196Janoshik2026-Q298.865.7390.6Supplier-supplied0PASS
AX-2026-042363HJHJ-2605-A4196Nordanalyt2026-Q299.215.8996.9Supplier-supplied0PASS
AX-2026-042365HJHJ-2605-A4196Janoshik2026-Q299.565.6189.6Supplier-supplied1MARGINAL
AX-2026-042364HJHJ-2605-A4196Janoshik2026-Q298.375.9097.1Buyer-sourced1FAIL
AX-2026-042358HJHJ-2605-A4196Medutest2026-Q299.205.83—Supplier-supplied0PASS
AX-2026-042366HJHJ-2605-A4196Janoshik2026-Q299.085.25—Supplier-supplied0PASS